SNY — Sanofi (Stock)

Price: $41.66 · 1 day: -2.00% · 5 days: -2.18% · 1 month: -8.82% · YTD: -14.03%
As of 2026-09-23 20:00 UTC.

52-week range: $40.89 – $52.68 (currently at 7% of the range).

The read

SNY is in a downtrend, momentum soft. $42.31 is the level overhead; $41.33 the first support below.

6 of 6 technical checks lean bearish.

• Price vs 50-day: below
• Price vs 200-day: below
• 50d vs 200d avg: below
• MACD: bearish
• RSI momentum: 25
• 5-day tape: -2.2%

Key levels

Indicators

Next earnings: 2026-10-30.

Latest SNY news

• S2S China Announces 2026 Finalists, Ten Standout Teams Set to Pitch Global Investors at Westlake University — S2S China, co-hosted by RA Capital Management and Qiming Venture Partners, has announced ten finalist biotech startup teams for its inaugural 2026 symposium. Selected from roughly 20 semifinalists after rigorous review, (PR Newswire, 2026-09-20)
• S2S China Announces 2026 Finalists, Ten Standout Teams Set to Pitch Global Investors at Westlake University — S2S China, the inaugural China chapter of the Science2Startup symposium co-hosted by RA Capital Management and Qiming Venture Partners, has announced ten finalist biotech startup teams selected from a competitive applica (PR Newswire, 2026-09-20)
• Marengo Therapeutics Completes Enrollment in Phase 1/2 STARt-001 Monotherapy Cohorts and Strengthens Leadership to Advance Invikafusp Alfa Toward Late-Stage Development — Marengo Therapeutics announced completion of enrollment in the monotherapy cohorts of its Phase 1/2 STARt-001 clinical trial evaluating invikafusp alfa across eight PD-1-resistant solid tumor types, with updated results (PR Newswire, 2026-09-09)
• AI Speeds Drug Ideas But Creates Costly Testing Bottlenecks — Artificial intelligence is accelerating the drug discovery process by generating new pharmaceutical candidates more quickly, but this advancement is creating a significant bottleneck in the clinical testing phase. While (Bloomberg Business, 2026-09-03)
• Fantasy M&A: the recipe for a European champion — The European Union has unveiled new merger guidelines designed to facilitate corporate consolidations to help the continent's companies compete with US and China rivals, reversing its previous restrictive stance. The shi (Financial Times News, 2026-09-03)
• The Oral PCSK9 Inhibitor Market Enters High-Growth Phase Owing to the Approval of Merck's LIPFENDRA and the Emergence of Oral PCSK9 Inhibitor Drugs, Including, AstraZeneca's AZD0780, Aqur's AQR-008, and Others | DelveInsight — The PCSK9 inhibitors market reached USD 3 billion in the 7 major markets in 2025 and is entering a high-growth phase driven by rising cardiovascular disease prevalence and the recent FDA approval of Merck's LIPFENDRA, th (PR Newswire, 2026-09-01)
• Novartis' MS Pill Trial Success Boosts Blockbuster Prospects — Novartis AG's experimental multiple sclerosis treatment, remibrutinib, successfully met endpoints in two late-stage clinical trials, demonstrating reduced relapses and brain lesions compared to the control group. This po (Bloomberg Business, 2026-09-01)
• Electra Files for IPO to Advance Immune Disease, Cancer Drugs — Electra Therapeutics Inc., a San Francisco-based biotechnology company, has filed for an initial public offering to fund its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer. The filing capi (Bloomberg Business, 2026-08-28)

Explore more

Interactive SNY chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs